Results Patient characteristics: subtype 1a:86%, 1b:14%; Liver stiffness >9.5kPa:14%, no cirrhosis; Interleukin 28B rs12979860 SNP genotype C/C:29%, C/T:48%, T/T:24%; Treatment-naïve:71%, prior relapse:29%; All patients on combined antiretroviral therapy (tenofovir/emtricitabine/raltegra-vir); GSI-IX chemical structure Mean CD4+ T-lymphocyte (CD4+) count:545±193cells/ μL. Fourteen patients (67%) had a RVR and were eligible for the shortened W28 arm, while 7(33%) patients were allocated to the W48 arm. Three patients are still on treatment. No

breakthrough or relapse occurred in the W28 arm, resulting in a SVR12 rate of 100%(12/12). In the W48 arm, the SVR12 rate was (50%(3/6)), as 3 patients met the treatment week 12 futility rule. Thus, the preliminary overall SVR12 rate was 83%(15/18). Grade 3/4 hematologic abnormalities were observed in 5(24%) patients, while 9(43%) patients developed a CD4+ count <200cells/μL. PEGIFN and RBV dose reductions were necessary in 1(5%) and 10(48%) patients, respectively. Erythropoietin and granulocyte colony-stimulating factor analogues were administered in 7(33%) and 6(29%) patients, respectively, and 2(10%) patients received blood transfusions. All patients had at least one adverse event, while serious adverse events related click here to bacterial infections and exhaustion were observed in 5(24%) patients. Conclusions This is the first study to

validate the concept of response-guided triple therapy in HIV/HCV-GT1. The majority of patients were eligible for response-guided shortening of treatment duration to W28 and all of these patients had a SVR12. If second-generation direct-acting antivirals are not available, W28 of BOC-based triple therapy may be recommended for HIV/HCV-GT1 with RVR. Disclosures: Mattias Mandorfer – Consulting: Janssen; Grant/Research Support: MSD, Roche; Speaking and Teaching: Janssen, Roche, Bristol-Myers Squibb, Boehringer Ingelheim Michael Trauner – Advisory Committees or Review Panels: MCE MSD, Janssen, Gilead, Abbvie; Consulting: Phenex; Grant/Research Support: Intercept, Falk Pharma, Albireo; Patent Held/Filed: Med Uni Graz (norUDCA); Speaking and Teaching: Falk Foundation, Roche, Gilead Markus

Peck-Radosavljevic – Advisory Committees or Review Panels: Bayer, Gilead, Janssen, BMS, AbbVie; Consulting: Bayer, Boehringer-Ingelheim, Jennerex, Eli Lilly, AbbVie; Grant/Research Support: Bayer, Roche, Gilead, MSD; Speaking and Teaching: Bayer, Roche, Gilead, MSD, Eli Lilly Thomas Reiberger – Grant/Research Support: Roche, Gilead, MSD, Phenex; Speaking and Teaching: Roche, Gilead, MSD The following people have nothing to disclose: Sebastian Steiner, Philipp Schwabl, Berit A. Payer, Maximilian C. Aichelburg, Gerold Lang, Katharina Grabmeier-Pfistershammer Background: Liver transplants (LT) for hepatitis C virus (HCV) cirrhosis show an increased mortality compared to LT for most other causes of liver disease. By more successfully eradicating HCV, new direct antiviral agents (DAAs) may improve the mortality of this group.